Literature DB >> 2836342

Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.

M R Zalutsky1, A S Narula.   

Abstract

A method is described for labeling proteins with 7.2 h half-life 211 At. The alpha particle-emitting nuclide was coupled to goat IgG using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate. The reaction and purification sequence requires about 2 h to produce 211 At-labeled IgG in 25-40% radiochemical yield. Comparative blood clearance measurements in mice suggest that the 211 At-labeled IgG conjugate is stable in vivo.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2836342     DOI： 10.1016/0883-2889(88)90176-1

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum A        ISSN： 0883-2889


  17 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

Review 2.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

3.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

4.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Hirohisa Nakamae; Yun Chen; Donald K Hamlin; Erlinda B Santos; Brian T Kornblit; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

Review 5.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

6.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

Authors:  M R Zalutsky; P K Garg; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

Review 8.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

9.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

10.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.